Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex, Inc. approved a one-for-twenty-two Reverse Stock Split of its common stock, effective at 12:01 a.m. Eastern Time on July 16, 2026. Every 22 outstanding shares will convert into 1 share, with fractional positions rounded up to the next whole share. Based on 11,108,577 shares outstanding on July 13, 2026, Genprex estimates about 504,936 shares will be outstanding after the split. The split does not change par value or authorized share count, and outstanding options and warrants will be proportionally adjusted.
The company is using this split as part of efforts to address Nasdaq’s $1.00 minimum bid price requirement after receiving a June 10, 2026 delisting notice and requesting a hearing before a Nasdaq panel. Genprex cautions that the split may not restore compliance and could negatively affect share price, liquidity and market capitalization, with delisting potentially impairing capital-raising ability and overall business.
The company also highlights progress in its REQORSA gene therapy lung cancer program, including ongoing Phase 2 expansion enrollment in the Acclaim-1 and Acclaim-3 trials, FDA Fast Track and Orphan Drug designations, and emerging biomarker data (TROP-2 and PTEN) that may guide patient selection and optimize outcomes.
Genprex, Inc. reports that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering the use of REQORSA Gene Therapy (quaratusugene ozeplasmid) with PD-1 or PD-L1 antibodies to treat both non-small cell and small cell lung cancer. This patent builds on earlier REQORSA combination patents already granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, Korea, Australia and Israel, further reinforcing the company’s global intellectual property position. Genprex believes the Canadian patent provides important protection for therapeutic combinations now being evaluated in the Acclaim-3 clinical trial. The company highlights Canadian Cancer Society data showing lung and bronchus cancer is the most commonly diagnosed cancer in Canada and the leading cause of cancer death, underscoring the potential need for new treatment options.
Genprex, Inc. reported results from its 2026 annual stockholders meeting, where investors approved an Amended and Restated 2018 Equity Incentive Plan adding 1,850,000 shares of common stock for potential equity awards. The plan now runs through April 15, 2036.
Stockholders also re-elected Jose Antonio Moreno Toscano and Ryan M. Confer as Class III directors and ratified WithumSmith+Brown, PC as auditor for the year ending December 31, 2026. An advisory vote approved compensation for named executive officers.
Shareholders further authorized an amendment to the certificate of incorporation allowing a reverse stock split at a ratio between 1-for-5 and 1-for-50, which the board may implement at its discretion any time before December 31, 2027.
Genprex, Inc. reported that Nasdaq has determined to delist its common stock after the shares closed below $1.00 for 30 consecutive business days, violating the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. Because Genprex executed a reverse stock split on October 21, 2025, it is not eligible for a standard 180-day compliance period under Listing Rule 5810(c)(3)(A)(iv). The company plans to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action during the process and any extension period the Panel may grant.
Genprex added a risk factor explaining that failure to regain and maintain compliance with Nasdaq’s continued listing standards could lead to delisting, potentially harming its stock price, liquidity, and ability to access capital markets. The company states it intends to take definitive steps to meet the bid price requirement, including considering another reverse stock split if appropriate, while cautioning there is no assurance of success and noting possible negative effects of a reverse split on price and liquidity.
Genprex, Inc. is registering a shelf offering to sell up to $250,000,000 of securities, which may include common stock, preferred stock, warrants, debt securities, subscription rights and units, pursuant to a prospectus dated June 5, 2026.
The filing replaces a prior registration and includes $76,143,570.21 of unsold securities carried forward from the prior registration. The prospectus discloses a public float of $15,812,904 (based on 10,905,451 non-affiliate shares at $1.45) and states that net proceeds will be used for working capital and general corporate purposes.
Genprex, Inc. filed an 8-K to highlight new clinical data from an abstract presented at the 2026 ASCO Annual Meeting by its research collaborators. The work examined predictive biomarkers in lung cancer patients treated with its lead gene therapy candidate, Reqorsa (quaratusugene ozeplasmid).
The abstract reported that in Non-Small Cell Lung Cancer patients from Genprex’s Acclaim trials, Trop-2 H-scores above 100 and PTEN H-scores below 100 were associated with longer progression-free survival. In Small Cell Lung Cancer patients, Trop-2 levels were low and PTEN expression did not correlate with progression-free survival.
Genprex also found that NSCLCs with strong (3+) Trop-2 staining showed a near-significant relationship with progression-free survival, and plans to further study high Trop-2 expression as a potential biomarker for Reqorsa. The filing reiterates standard forward-looking statement cautions and related development and financing risks.
Genprex, Inc. reported that its research collaborators presented positive preclinical results for its diabetes gene therapy candidate PM (GPX-002) at the 2026 ASGCT Annual Meeting. In Type 2 diabetic mouse models on a high-fat diet, pancreatic delivery of AAV-Pdx1/MafA gene therapy reversed hyperglycemia and improved glucose-stimulated insulin secretion, indicating better β-cell function.
Electron microscopy showed more total and mature insulin granules and fewer immature granules after treatment, while transcriptomic analysis suggested β-cells shifted toward a more mature state. Genprex believes this preclinical work is a pivotal step toward a potentially transformative Type 2 diabetes treatment, with a technique the company views as technically translatable to humans.
Genprex, Inc. reported another quarterly loss as it advances its gene therapy pipeline for lung cancer and diabetes. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.46M as operating expenses rose to $4.49M.
Cash and cash equivalents increased to $18.05M, driven mainly by $13.36M of net proceeds from common stock sales under its at-the-market program, raising total stockholders’ equity to $16.93M. Shares outstanding grew sharply to 9,044,856 at March 31, 2026 and 10,586,402 as of May 11, 2026.
The company is enrolling patients in Phase 2 portions of its Acclaim-1 and Acclaim-3 REQORSA lung cancer trials, both benefiting from FDA Fast Track status, with Acclaim-3 also holding Orphan Drug Designation. Its GPX-002 diabetes gene therapy remains in preclinical development under expanded University of Pittsburgh licensing.
Management estimates existing cash will fund operations into the second half of 2027 but acknowledges recurring losses, lack of revenue, and dependence on future financings create substantial doubt about Genprex’s ability to continue as a going concern.
Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B) and Waqas Khatri reported beneficial ownership of 249,788 shares of Genprex, Inc. Common Stock issuable upon exercise of warrants. The reported stake equals 2.69% of the class based on 9,044,856 shares outstanding as of March 27, 2026. The issuable shares are subject to a 9.99% beneficial ownership blocker. Holdings are reported "as of" March 31, 2026.
Genprex, Inc. announced that the Israel Patent Office has granted a patent covering the use of its REQORSA Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. This extends Genprex’s intellectual property around REQORSA beyond prior patents granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.
REQORSA is initially being developed with approved cancer drugs to treat lung cancer, where preclinical studies have shown it can complement targeted drugs and immunotherapies. The company highlights Israeli public health data showing lung cancer is a leading cause of cancer deaths, underscoring the medical need in that market.